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Abstract: The hepatitis C virus (HCV) treatment landscape has rapidly changed over recent 
years. The development of direct-acting antiviral (DAA) agents that specifically target various 
steps in the HCV lifecycle has revolutionized therapeutic options for patients with HCV, with the 
development  of  highly  effective  and  well-tolerated  oral  interferon-free  (IFN-free)  regimens. 
There  are  several  DAAs  that  have  been  approved  and  others  that  are  currently  in 
development, targeting different nonstructural HCV or host proteins that are essential for HCV 
replication. Data on virological response in different HCV genotypes and patients subgroups 
are well established in the literature, while results on clinical outcome are much more limited.
In this thesis, I will describe real-life virological and clinical outcome with DAA therapy in a large 
cohort of patients with HCV treated in clinical practice in the Veneto Region. For this purpose, 
we have used the NAVIGATORE web-platform that is recording and monitoring all HCV-DAA 
based  treatments  in  the  Veneto  region  and  we  have  assessed  virological  and  clinical 
outcomes of  DAAs treatment in 3  subgroups of  patients:  1)  HCV infected  cirrhotics (both 
compensated and decompensated) to clarify drugs efficacy and clinical outcomes, including 
long term benefits of treatment, 2) Patients with extrahepatic manifestations due to HCV and 
3) patients with HCV aged > 70 years. 
Our analysis has been based on a cohort  of  2946 cirrhotic patients. DAAs were safe and 
efficacious in these patients, including those with advanced, or decompensated cirrhosis. SVR 
rates  for  most  genotypes  were  excellent,  but  the  initially  used  Sofosbuvir  plus  Ribavirin 
regimens were suboptimal in HCV-1 and HCV-3 infected patients. Efficacy was not significantly 
affected by common comorbidities but it was reduced in patients with Child B cirrhosis. Severe 
adverse event were unusually: tolerability and safety were excellent in patients with Child A 
cirrhosis,  while  were  reduced  in  Child  B  patients,  particularly  when  treated  with  Ribavirin 
containing regimens . Patients with decompensated cirrhosis often showed an improvement in 
Child  scores  and  patients  with  compensated  cirrhosis  showed  a  reduced  incidence  of 
complications, compared to the expected rates in the natural history of untreated disease. The  
"de novo" incidence of HCC was also reduced during and after DAA and the incidence of HCC 
recurrence  not  increased  during  and  after  DAAs.  A subgroup  of  patients  developed  an 
aggressive type of HCC during therapy, and this was more frequent in non-responders, an 
observation that  certainly deserves further  evaluation.  Extrahepatic  manifestations  of  HCV 
infection also improved with successful antiviral therapy. Moreover, a sub-analysis in a group 
of patients over 70 years, the "elderly group", confirmed excellent safety and efficacy of DAAs 
also in this setting.
OUTCOMES VIROLOGICI E CLINICI OTTENUTI CON LA TERAPIA ANTIVIRALE ORALE IN 
PAZIENTI CON CIRROSI HCV-CORRELATA
Abstract: Il panorama del trattamento dell'epatite C si è rapidamente modificato negli ultimi 7  
anni.  Lo sviluppo di  antivirali  diretti  (direct-acting antiviral  = DAA),  che hanno come bersaglio  
diversi punti nel ciclo vitale del virus dell'epatite C (HCV), ha rivoluzionato le opzioni terapeutiche  
per i pazienti con epatite C, con la disponibilità di  regimi orali  (non più basati sull'interferone) 
altamente efficaci  e  ottimamente tollerati.  Ci sono diversi DAAs attualmente in  sviluppo o già 
approvati,  che  hanno  come  bersaglio  diverse  proteine  di  HCV  non-strutturali  o  altri  targets  
essenziali per la replicazione di HCV. I dati di risposta virologica nei diversi genotipi HCV e in  
diversi  sottogruppi  di  pazienti  sono  ben  documentati  in  letteratura,  mentre  i  risultati  sugli 
outcomes clinici sono molto più limitati.
In questa tesi sono descritti gli outcomes "real-life" clinici e virologici, ottenuti con la terapia con 
DAA in una larga coorte di pazienti con epatopatia HCV correlata, trattati nella pratica clinica nella 
Regione  Veneto.  A tal  proposito,  abbiamo usato  la  piattaforma NAVIGATORE,  che registra  e 
monitorizza tutti i trattamenti per HCV DAA-based in Veneto, ed abbiamo valutato gli outcomes 
clinici e virologici ottenuti con trattamenti con DAA in 3 gruppi di pazienti: 1) pazienti con cirrosi 
HCV correlata (sia compensati che scompensati) allo scopo di verificare l'efficacia e gli outcomes 
clinici,  inclusi  i  benefici  a  lungo  termine  del  trattamento,  in  questa  categoria  di  pazienti.,  2)  
pazienti con manifestazioni extraepatiche da HCV e 3) un gruppo di pazienti con età > 70 anni.
La nostra analisi ha considerato una coorte di 2946 pazienti cirrotici. I DAAs si sono dimostrati 
sicuri ed efficaci in questi pazienti, inclusi quelli con cirrosi avanzata o scompensata. I tassi di  
SVR per la maggior parte dei genotipi sono stati eccellenti, ma i regimi usati inizialmente con solo 
sofosbuvir e ribavirina erano subottimali nei pazienti con infezione da genotipo 1 e 3.
L'efficacia non è stata significativamente influenzata dalla presenza delle più comuni comorbidità, 
ma è risultata ridotta nei pazienti con cirrosi in Child B. Gli effetti collaterali gravi sono rari: la  
tollerabilità e la sicurezza sono state eccellenti nei pazienti sia con fibrosi F3 che in quelli con  
cirrosi in Child A, mentre sono risultate ridotte nei pazienti in Child B, particolarmente quando 
trattati  con  regimi  contenenti  ribavirina.  I  pazienti  con  cirrosi  scompensata  hanno  spesso 
presentato un miglioramento nel punteggio di Child ed i pazienti con cirrosi compensata hanno 
mostrato una ridotta incidenza di complicanze rispetto ai tassi attesi nella storia naturale della 
malattia non trattata. L'incidenza di HCC "de novo" è risultata ridotta durante e dopo terapia con 
DAA e l'incidenza della recidiva di HCC non è aumentata durante o dopo terapia con DAA. Un  
sottogruppo di questi pazienti ha sviluppato un tipo di HCC più aggressivo durante la terapia, e 
ciò  si  è  verificato  più  frequentemente  nei  pazienti  non-responder  alla  terapia,  osservazione 
questa che certo merita ulteriori valutazioni. Anche le manifestazioni extraepatiche HCV correlate  
sono  migliorate  in  relazione  al  successo  terapeutico.  Inoltre  una  sub-analisi  in  un  gruppo  di  
pazienti ultra-settantenni ("gruppo Anziani") ha confermato una sicurezza ed una efficacia della  
terapia con DAA eccellenti anche in questo setting.
INTRODUCTION
Infection  with  the  hepatitis  C  virus  (HCV)  remains  a  significant  global  health  issue. 
Chronic hepatitis C is a leading cause of cirrhosis and hepatocellular carcinoma and of 
liver related deaths. Moreover, chronic HCV infection has been shown to contribute to 
extrahepatic morbidity and mortality, causing lymphoproliferative disorders, vasculitis, and 
contributing to development of type 2 diabetes and associated cardiovascular disease. 
Hepatitis C is a slowly progressing liver disease, with cirrhosis occurring about 20–30 
years after infection. Cirrhosis cannot be viewed as a single, irreversible end-stage phase  
of HCV disease but rather as a spectrum characterized by progressive increase in hepatic 
venous  pressure  gradient  and  decrease  in  liver  function,  finally  leading  to  hepatic 
decompensation. The occurrence of varices initiates the second stage of cirrhosis, and 
portal hypertension progresses as the third stage defined by the development of ascites.  
Variceal  haemorrhage initiates the fourth stage. The occurrence of bacterial  infections 
delineates an additional fifth stage of cirrhosis with high mortality rates. Variceal bleeding,  
bacterial  infections,  hepatorenal  syndrome,  acute  on  chronic  liver  failure  and 
hepatocellular  carcinoma  are  the  leading  causes  of  death.  With  the  ageing  HCV 
population, there is a growing burden of complications of chronic HCV infection (CHC),  
including cirrhosis, decompensated liver disease, and hepatocellular carcinoma. These 
complications are expected to triple over the next 15 years. However, CHC is curable, and 
viral eradication is associated with improved patient survival and reduced complications of  
CHC.
For the past decade, the only therapy for HCV has been pegylated-interferon combined 
with  ribavirin  (PR).  Unfortunately,  this  therapy  was  limited  by  the  significant  toxicity, 
inconvenience  of  administration  via  injection,  extended  treatment  duration  (up  to  48 
weeks) and suboptimal response rates (overall response rates 54%–56%). Furthermore, 
not all  patients were eligible for PR therapy. Thus, there was an urgent need for more 
efficacious and better-tolerated treatments for HCV.
In 2010 the first proof of concept study showed that an IFN-free using a combination of  
direct-acting antivirals (DAAs) agents was possible and highly effective. The development  
of a cell  culture system for HCV and subsequent detailed characterization of the HCV 
lifecycle have allowed the development of new therapies that directly target steps in the 
HCV replication cycle, so called direct-acting antivirals. The development of these DAAs 
has rapidly evolved and has radically changed the HCV treatment paradigm to allow IFN-
free  regimens.  Interferon  (IFN)-free  treatments  are  now  the  treatment  of  choice  for 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DRUG CLASS POTENCY GENOTYPE  GENETIC BARRIER DDI SAFETY IN DECOMPENSATED
ProteaseInhibitors
Simeprevir + HCV-1,4 low ++ no
Paritaprevir
Grazoprevir 
++
++
HCV-1,4
HCV-1,4
low
low
++
±
no
no
NS 5A Inhibitors
           Daclatasvir ++ pangeno low + yes
Ledipasvir ++ HCV-1,3,4 low + yes
Ombitasvir
Elbasvir
Velpatasvir
++
++
++
HCV-1,4
HCV-1,4
pangeno
low
low
low
++
±
±
?
no
no
NS5B Polymerase 
inhibitors
NNUC
Dasabuvir +/- HCV-1 low ++ no
NUC
Sofosbuvir ++ pangeno high ± yes
Table 1: The various classes of agents developed to treat HCV (DAAs). 
Available DAAs target proteins involved with the replication of HCV and include NS5B nucleotide polymerase inhibitors, NS5B non-
nucleoside polymerase inhibitors, and NS5A replication complex inhibitors and protease inhibitors.
Direct-acting antiviral agents
The ideal DAA has a high barrier to resistance, pangenotypic activity, picomolar potency,  
few drug–drug interactions (DDIs),  minimal  toxicity,  and a pharmacokinetic  profile  that  
allows once daily dosing. The genetic barrier to resistance is the number of amino acid  
substitutions required to confer resistance to a DAA. DAAs with a low barrier to resistance 
only require 1–2 substitutions in order to render the drug ineffective, whereas a DAA with  
a high genetic barrier to resistance requires 3 or more substitutions, and hence drugs with 
a  high  barrier  to  resistance  are  preferred  as  the  backbone  of  many  IFN-free  DAA 
combinations. In addition, the replication fitness of resistance-associated variants (RAVs)  
needs to  be considered,  as RAVs with  poor  replication fitness may not  emerge to be  
dominant under DAA selection pressure (e.g., S282T RAV with sofosbuvir), whereas RAVs 
with preserved replication fitness emerge rapidly to become dominant (e.g., Q80K in the 
context of simeprevir)(2).
NS3/4A protease inhibitors
NS3/4A protease inhibitors (PIs) block the catalytic site of the NS3/4A protease, resulting  
in failure of polyprotein cleaving and processing. The first  DAAs to be developed and 
licensed for the treatment of HCV genotype 1 (HCV-1) were the NS3/4A PIs, telaprevir, 
and boceprevir. While offering a significant improvement in sustained virological response 
rates (SVRs) for HCV-1, these agents required combination with PR and had significant  
additional toxicity to PR, a large daily pill burden, and significant DDIs. Simeprevir (SMV),  
a second-wave first-generation NS3/4A PI with a more favourable pharmacokinetic profile  
allowing once daily dosing, with less additional toxicity on top of PR therapy and improved 
genotype coverage, has since been developed and has  rapidly replaced telaprevir and 
boceprevir. Second-generation NS3/4A PIs offer the advantages of higher potency and  
improved adverse event (AE) profiles, while still  allowing daily dosing. (see paritaprevir  
PTV, grazoprevir GZR...)(2).
NS5B polymerase inhibitors
The NS5B polymerase is highly conserved across all HCV genotypes, and thus is an ideal 
target  for  DAA development.  NS5B polymerase  inhibitors  are  divided  into  two  types:  
nucleos(t)ide NS5B inhibitors and non-nucleos(t)ide NS5Binhibitors.
Nucleos(t)ide  NS5B inhibitors:  Nucleos(t)ide  analogs  of  the  NS5B polymerase  act  as 
chain terminators within the catalytic site of the NS5B polymerase (nucleotide inhibitors  
[NIs]).  These  agents  provide  a  high  genetic  barrier  to  resistance,  have  pangenotypic 
activity (as the NSB5 polymerase is highly conserved), high potency, and limited DDIs, 
and offer daily dosing. SOF is the only NI that has reached the market to date. 
Nonnucleos(t)ide NS5B inhibitors: These agents bind to different allosteric sites of the 
NS5B polymerase,  which  result  in  conformational  changes,  rendering  the  polymerase 
ineffective.  These  domains  are  highly  variable  between  genotypes,  and  hence  these 
agents only have activity against specific genotypes. This class of agents also has a low 
barrier to resistance (2).
NS5A inhibitors
The  NS5A protein  has  multiple  functions  and  is  important  in  viral  replication  and 
assembly.  Inhibitors  of  the  NS5A protein  have  been  shown  to  be  potent  antivirals, 
although the exact mechanism by which these agents interact with the NS5A protein and 
inhibit HCV replication remains unclear. Several NS5A inhibitors have now been licensed, 
including  daclatasvir  (DCV),  ledipasvir  (LDV),  ombitasvir  (OBV),  elbasvir  (EBR),  
velpatasvir (VEL)(2).
Therapy of chronic hepatitis C has been revolutionized by the DAAs. These drugs, given 
orally in different combinations, are safe and highly effective in eradicating HCV in all the  
different  categories  of  HCV  infected  patients,  including  those  with  advanced,  or 
decompensated,  cirrhosis,  who  were  not  suitable  candidates  for  IFN-containing 
treatments  due  to  contraindications.  The  combinations  of  DAAs  recommended  by 
guidelines are evolving, and those proposed by the European Association for the Study of  
the Liver are described in the table, with schedules and regimens proposed for cirrhotic  
patients with compensated disease (11).
Table 2: Treatment recommendations for HCV patients with chronic hepatitis C with compensated (Child-
Pug A) cirrhosis (from EASL recommendations 2016)
Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of 
liver and non-liver complications
Data on clinical outcomes after HCV infection eradication have recently started to become 
available.  Nahon  et  al  (12),  analysing  the  French  Cir-Vir  cohort,  have  confirmed  a 
significant reduction in clinical events, both liver-related or non-liver related, in a group of  
patients achieving SVR with IFN-based therapy and also in a smaller subgroup of IFN-
free treated cirrhotics. They found that achievement of SVR reduces overall mortality. This 
author  clearly  showed that  achieving  SVR in  HCV-infected  cirrhotic  patients  leads  to 
improved prognosis: SVR influenced the incidence of liver complications, including HCC 
and  mortality,  and  had  also  a  positive  impact  on  the  occurrence  of  extrahepatic  
manifestations.  But  they  also  concluded  that  the  follow-up  after  SVR in  DAA-treated 
patients is still too short to allow drawing any definite conclusion on this point.
In general, patients with decompensated cirrhosis (Child-Pugh B/C) have lower response 
rates than patients with compensated cirrhosis (Child-Pugh A), may be for reduced drug 
delivery due to shunting leading to HCV reservoirs, altered drug metabolism and uptake 
(due  to  impaired  liver  synthetic  function)  or  impaired  immune  responses  which  are 
common  in  severe  cirrhotic  patients.  Obviously,  among  patients  with  decompensated 
cirrhosis, the IFN-free regimens are far better tolerated as compared to the PegIFN and 
RBV combination therapy. However, as more real-world data are emerging, some safety 
issues regarding the use of DAAs among those patients with the most advanced liver 
disease have also been arisen. Some patients with hepatic decompensation developed 
severe  drug-induced  liver  injury  leading  to  death  and  liver  transplantation.  Lactate  
acidosis have described among patients treated with sofosbuvir-based regimens, with or 
without  the  addition  of  RBV.  Occurrence  of  hepatic  decompensation  during  antiviral  
treatment has been reported for some DAA regimens, leading the FDA to discourage the 
use of dasabuvir,  ombitasvir,  and paritaprevir/ritonavir for patients with decompensated 
liver disease. Other protease inhibitors may also not represent an ideal class of DAAs for  
patients with the most severe cirrhosis, considering safety issues which were encountered 
with the first-generation protease inhibitors telaprevir and boceprevir among patients with  
cirrhosis and low platelets or low albumin levels  (13).  Because of the beneficial  safety 
profile of the DAAs, our experience with antiviral  therapy in patients with chronic HCV 
infection  and  decompensated  cirrhosis  is  increasing  rapidly.  Still,  because  these 
therapeutic options have just surfaced, studies with sufficient follow-up to assess the true 
clinical  impact  of  IFN-free  therapy  among  the  patients  with  the  most  advanced  liver  
disease have to be awaited. In the meantime, several interesting observations in the short  
term  have  been  presented,  which  focus  on  the  Model  for  End-Stage  Liver  Disease 
(MELD) score. Deterding et al. treated 34 HCV-infected patients with Child-Pugh B/C with 
various IFN-free regimens. At 12 weeks post-treatment, the MELD score improved in 68%, 
remained stable in 23%, and worsened in 10% of patients. Based on the first experiences 
in England, Foster et al. reported the change in MELD score 4 weeks after the cessation  
of DAA therapy. Of the 220 patients, 47.7% had no significant change in MELD score; in 
41.8% patients, MELD score improved by ≥2 points; and in 10.5% patients, MELD score 
worsened  by  ≥2  points.  Additional  analyses  indicated  that  the  MELD  score  more 
frequently  improved  rather  than  declined  among  younger  patients  (<65  years)  and 
patients  with  a  high  albumin  level  (>35  g/L)  .Still,  MELD  improvement  was  mostly 
moderate, so the important question of whether liver transplantation can really be averted 
remains. If not, the slight improvement in MELD score may actually negatively impact the 
patient’s chances on the waiting list (13, 29).
Liver-related  morbidity  and  mortality.  Most  of  the  Western  studies  that  assessed  the 
association  between  HCV  eradication  with  IFN-based  therapy  and  hepatic 
decompensation or HCC have solely included patients with advanced liver disease, who 
are most at risk for these cirrhosis-related complications. However, as we have previously 
depended  on  IFN-based  treatment  regimens,  most  available  studies  predominantly 
included cirrhotic patients with relatively favourable characteristics. These studies showed 
that the incidence in liver failure was markedly reduced among patients with chronic HCV 
infection  and  advanced  liver  fibrosis  who  attained  SVR.  Interestingly,  this  beneficial  
outcome became apparent rather soon after HCV clearance. Hereafter, larger studies with 
longer follow-up duration not only confirmed these results but also showed a significant 
association between SVR and a reduced occurrence of HCC, with strong hazard ratios  
(HRs) adjusted for many potential confounders. In a recent meta-analysis, in which the 
results of all available cohort studies among patients with advanced liver disease were 
pooled, the results indicated that within this population the HR of SVR for the occurrence  
of HCC was 0.23. The combination of several studies that included patients with all stages 
of  fibrosis  resulted  in  a  pooled  HR  of  0.24  regarding  SVR  and  HCC  occurrence.  
Considering the potential benefits of SVR in these cirrhosis-related morbidities, it is not  
surprising  that  patients  with  cirrhosis  who  clear  their  chronic  HCV  infection  have  a  
reduced liver-related mortality (24). Still, it is worthy to note that patients with advanced 
liver disease are not free from cirrhosis-related complications following HCV eradication.  
A combined cohort including 1000 patients with advanced liver fibrosis and IFN-induced 
SVR showed that the annual risk of HCC remains at about 1% following HCV eradication 
in  patients with cirrhosis.  The risk of  HCC depends on age, the presence of diabetes  
mellitus,  and laboratory markers of liver disease severity.  One may thus expect still  a 
significant incidence of HCC following successful  antiviral  therapy in the era of DAAs, 
which will enable older patients with more advanced liver disease to attain SVR (13).
Extrahepatic  consequences. While  a large number of  studies indicated potential  liver-
related benefits of SVR, more recent efforts have focused on the association between 
antiviral  therapy and extrahepatic  disease.  With  respect  to  patient-reported outcomes, 
eradication of HCV infection decreases both the frequency and the severity of fatigue.  
Even a few years ago, it  was reported that the risk of diabetes mellitus is about three 
times  lower  among  patients  with  SVR  as  compared  to  patients  without  SVR.  The 
deteriorating  consequences  of  diabetes  mellitus  are  diverse  but  surely  include  renal  
failure and cardiovascular events. A reduced incidence of both of these solid endpoints in  
cases of  antiviral  therapy use was recently  shown in  a  nationwide cohort  study from 
Taiwan.  The cumulative 8-year  incidences of  end-stage renal  disease,  acute coronary 
syndrome, and ischemic stroke, were significantly lower among treated as compared to 
untreated patients (p<0.05 for all), and the effect of antiviral therapy remained statistically  
significant in multivariate analysis. Gragnani et al. showed that HCV eradication led to the 
disappearance  of  cryoglobulinemia  and  resolved  manifestations  of  the  mixed 
cryoglobulinemia syndrome in nearly all patients. Other potential extrahepatic benefits of  
SVR that  have  been  presented  within  recent  years  include  a  reduced  occurrence  of 
malignant lymphomas. Through these effects on extrahepatic morbidity, patients with SVR 
have not only a reduced liver-related mortality but also a reduced liver-unrelated mortality  
(13).
Clinical outcomes with DAA-Based SVR: HCC reccurrence and "de novo" HCC
If  the  high  rate  of  SVR  seems  constant  among  several  clinical  trials  testing  DAA 
combinations ,  the impact on complications of cirrhosis  is  still  unknown. We  can only 
speculate from the results of observational studies among compensated cirrhotic patients 
treated by IFN regimens. In these patients, SVR were obtained mostly by the combination 
IFN and ribavirin treatments and decreased the occurrence of liver decompensation, of 
hepatocellular carcinoma and of death.
The rate of hepatocellular carcinoma (HCC) occurrence is strongly decreased after SVR 
but not abolished with an incidence of HCC ranging from 0.4 to 2% per year after viral  
eradication with IFN based therapies. In contrast, the evidence of decreased liver related 
complications  after  viral  clearance  using  DAA is  still  scarce  (14).  An  intense  and 
controversial debate has been recently raised on which is the residual risk of developing 
hepatocellular carcinoma in cirrhotic patients treated with DAAs. This debate has been 
triggered by some reports suggesting that such risk might not be reduced, as it was in 
cirrhotic patients achieving SVR with IFN-based therapy, and could be even increased, 
expecially  in  cirrhotics  who  had  already  experienced  HCC,  having  been  successfully  
treated  for  it,  with  complete  radiological  response,  before  receiving  DAAs  treatment.  
These findings prompted other Authors to review and publish their data in similar clinical 
settings, generating a rather heterogeneous and controversial scenario that remains yet 
to be fully completed and understood.
HCC recurrence
Published data on HCC recurrence in HCV patients treated with DAAs after complete 
response to  HCC cure  have shown rates  of  HCC recurrence quite  variable  reflecting 
heterogeneity in study design, type of patients included and follow-up. The debate was 
generated by the report of Reig and coworkers (15). These Authors had initially observed 
a number of individual patients with previous, successfully cured HCC, who developed 
tumour recurrence after receiving antiviral  therapy with DAAs, despite successful  HCV 
eradication, and were impressed by the temporal relation between antiviral therapy and 
HCC recurrence. They decided to perform a systematic review of the cases treated with 
DAAs in  four  Referral  Hospitals  in  Spain  and were able  to  describe  58 patients  with 
treated  HCC (ablation,  resection,  or  chemoembolization)  with  a  complete  radiological 
response, who were then given all-oral  DAA combination therapy. The vast majority of 
patients achieved SVR 12. However, during a median follow-up period of 5.7 months after 
starting DAAs, 16 patients (27.6%) developed radiological evidence of HCC recurrence 
with a median time from DAAs start to tumour recurrence of only 3.5 months (range 1.1-8 
months). The observed HCC recurrence was thought by the Authors to be “surprisingly 
high” compared to the expected incidence in the natural history of successfully treated 
HCC, considering that the vast majority of the included HCC could be classified at low risk  
of  recurrence  (15).  This  conclusion  was  also  supported  by  comparison  with  HCC 
recurrence observed by the  Authors  in  a  prospective  study after  surgical  resection  in  
another prospective series (unpublished) after ablation (2.45% at 4 months and 27.6% at 
12 months) and in the double blind placebo controlled STORM trial. The highest rate of  
HCC recurrence (41.17%) was indeed observed in patients with a short time frame (<4 
months) between HCC treatment and last assessment of complete response by imaging. 
This observation was confirmed in the analysis of Cammà et al.(16) who extracted the 
Kaplan–Meier HCC recurrence estimation curves from Reig’s paper and showed that the 
probability of HCC recurrence during the first 6 months after starting DAAs was more than 
double (approaching 50%) in patients with a time frame between HCC treatment and last  
assessment of HCC complete response <6 months compared to the probability (<15%) 
estimated in patients with a longer time frame. This may suggest that the high rate of early  
tumour recurrence described by the Spanish Authors could have been driven mainly by  
individual cases, including those initially observed, initiated on DAAs shortly after HCC 
treatment. Data on early recurrence of HCC in cirrhotics patients treated with DAAs have 
also been reported by Conti et al. (17) These Authors described 59 patients with a history 
of previous HCC, treated with surgical resection, RFA, TACE, PEI and with a combination  
of  procedures.  All  patients  had  a  complete  tumour  response  and  were  treated  with 
approved oral  DAA combinations after  a  median interval  of  376 days (range 45-2706 
days). 53 of the 59 patients (89.8%) achieved SVR. However, during a 24 week post-
treatment follow-up 17 (28.8%-95% CI 17.76-42.07%) showed HCC recurrence, that was 
associated with younger age and with more severe liver fibrosis. The crude rate of HCC 
recurrence was almost identical  to that reported by Reig et al.  (28.8% vs 27.6%), but  
follow-up  after  DAAs  initiation  was  longer  leading  to  a  different  (lower)  time-based 
incidence. Also in this study, it was evident that patients with a previous HCC remain at  
risk  of  HCC  recurrence  after  treatment  with  DAAs,  even  when  HCV  is  successfully 
eradicated,  but  the  design  of  study  did  not  allow  to  define  whether  the  observed 
recurrence rate was increased, reduced or unmodified compared to what is expected in  
the natural history of the disease. Another study that has contributed to raise concern on  
HCC recurrence in patients treated with DAAs came from the Majo Clinic in the US where 
Yang et al.  (18) described their experience in HCV patients undergoing liver transplant 
with HCC and reported higher HCC recurrence (27.8%) in the patients who had received 
DAAs pre-transplant.  Other  studies,  have  not  confirmed  increased  incidence  of  HCC 
recurrence  in  patients  treated  with  DAAs.  The  French  report  on  the  different  ANRS 
collaborative prospective studies of HCV patients  (19) described recurrence of HCC in 
three distinct cohorts. (I) In the CO22 HEPATER Cohort, including 267 patients with an 
history of cured HCC, the rate of HCC recurrence was 12.7% (8.76×100 patients/year) in 
189  patients  who  had  received  DAAs  treatment  compared  to  20.5%  (7.92×100 
patients/year) of the 78 untreated patients. (II) In the CO12 CirVir cohort, incidences of 
HCC  recurrence  were  13.32×100  patients/year  in  13  DAAs  treated  patients  and 
20.76×100 patients/year among 66 untreated patients. (III) In the CO23 CUPILT cohort,  
including 314 patients undergoing liver transplant for HCV related HCC, HCC recurrence 
was seen in  only  2.2% of  the  cases  during  a  follow-up of  7±3 months  after  antiviral  
therapy. The Authors concluded that there was no evidence of an increased risk of HCC 
recurrence in patients treated with DAAs. A rather similar low rate of HCC recurrence in  
cirrhotic patients treated with DAAs has been reported also by Zavaglia et al. (20) and by 
Cheung et al.  (21) with incidence of 3.2% over a mean 8 months of follow-up and of  
6.29% over a mean 15 months follow-up. The heterogeneity of all these results most likely 
reflects the heterogeneity of the clinical setting they refer to, with a number of variables  
that  could  have  heavily  affected  HCC recurrence  rates.  Absence  in  many  studies  of 
matched untreated controls further complicates interpretation and do not allow to draw 
firm  conclusions.  Cabibbo  et  al. (22) have  recently  conducted  a  meta-analysis  of 
published studies of  HCV patients  with  adequate follow-up after  curative treatment of  
HCC, not receiving any type of antiviral therapy. The Authors analysed 11 such studies 
inclusive of 701 patients:  the estimated probability  of  HCC recurrence was 7.4% at 6  
months,  of  20% at  12 months  and of  47% after  24 months.  There  were  rather  large 
confidence intervals together with significant heterogeneity, largely expected, in relation to  
baseline  patients  and  tumour  characteristics  and  type  of  HCC  treatment.  These 
recurrence rates may be useful to design and stratify prospective observational studies 
able to assess more adequately the effect of DAA therapy on HCC recurrence. On this  
line, Petta et al. (23) have recently tried to compare retrospectively HCC recurrence rates 
in untreated patients with persistent HCV replication, and in patients achieving SVR with 
IFN-based therapy or with DAAs oral treatment. The results were suggestive for reduce 
risk of HCC recurrence in patients with SVR, without any difference between IFN-based 
and IFN-free (DAAs based) therapy.
"De novo" HCC in patients treated with antiviral therapy
Natural  history  studies  indicate  that  in  HCV  patients  the  risk  of  developing  HCC  is  
dependent  on  patient  age  and  gender,  stage  of  liver  disease  and  comorbidities  and 
cofactors such as type 2 diabetes, alcohol and HBV coinfection. In patients treated with  
IFN-based regimens, the residual risk of developing HCC was reduced (HR ranging from 
0.24 to 0.40), although not fully abolished in patients with SVR (residual risk ranging from 
0.33%/year to 1.40-2.00/year depending on patient age and stage of liver disease) (24, 
25). Recently, Nahon et al. (12) have reported data from a prospective study inclusive of 
1323  patients  with  compensated  cirrhosis  treated  with  antiviral  therapy  (mainly  IFN 
based).  A total  of  668  patients  achieved  SVR that  was associated  with  a  decreased 
incidence of hepatocellular carcinoma compared to patients not achieving SVR (hazard 
ratio 0.29, 95% CI: 0.19-0.43). Residual risk of developing HCC after SVR was associated 
with presence of metabolic syndrome and of type 2 diabetes. Incidence of “de novo” HCC 
after  DAAs therapy has been also investigated by Cheung et al.  (21) in  patients with 
advanced,  decompensated  cirrhosis.  These  Authors  described  377  cirrhotic  patients  
(Child B in 72.7%, Child C in 10.1%) without a previous diagnosis of HCC, treated with  
approved DAAs. HCC developed in 15 (3.9%) during the first 6 months after initiation of  
DAAs (notably five of these within the first 3 months) and in additional 10 (2.6%) at longer  
follow-up (6-15 months after initiation of antivirals). Patients with SVR had lower rates of 
HCC incidence compared to those without SVR and to untreated patients. Interestingly, a  
trend towards progressive reduction of the risk was observed over time in patients with  
SVR. In another retrospective study of 285 HCV patients with advanced liver disease 
(10% Child B) treated with DAAs in the absence of previous diagnosis of HCC, “de novo” 
occurrence of a liver tumour was seen in 3.16% (95% C.I.: 1.45-5.90) during the 24 weeks 
after antiviral treatment (17). This crude rate translates in an annual rate after initiation of 
DAAs not exceeding 4.2% and most likely lower, considering that patients were treated for 
12-24 weeks (most  of  them likely  for  24  weeks)  and then followed up for  24  weeks. 
Overall, 91.6% of patients achieved SVR and HCC occurred in 8.3% of patients without 
SVR and in 2.7% of those with SVR. A somehow high rate of “de novo” HCC after DAAs 
has been  reported  by  Cardoso  et  al.,  (26)  with  tumour  incidence  of  7.4% among 54 
patients  with  cirrhosis  (67%  with  Child  A)  treated  with  DAAs  in  Spain.  All  patients 
developing HCC had SVR12. In contrast, in the French prospective series of 167 cirrhotic  
patients  achieving  SVR with  DAAs,  only  1  (0.6%)  was found  to  develop HCC during 
follow-up (12).
AIM AND MATERIALS AND METHODS
Aim. Aim of this project was to assess virological and clinical outcomes of DAAs treatment 
in HCV infected cirrhotics (both compensated and decompensated) by studying a large 
cohort of patients treated with DAAs in the Veneto region. Furthermore we intended to 
assess virological responses and clinical outcomes in HCV patients treated with DAAs at  
an “elderly stage” i.e. > 70 years of age, as well as in patients with severe extra-hepatic  
manifestations of HCV, taking advantage from the fact that DAA treatment was allowed in 
Italy since the very beginning in these patients subgroups.
The  project  was  conducted  by  assembling  and  analysing  a  database  using  the 
NAVIGATORE web-platform, that – since January 2015- is recording and monitoring all  
HCV-DAA based treatments in the Veneto region (and more recently also in the Alto-Adige 
and Lombardia regions), in a network of Clinical Units coordinated by the Department of  
Molecular Medicine of the University of Padua.
NAVIGATORE is an acronym and means: Nuovi AntiVIrali per HCV: Gestione ATtraversO 
Registro degli Eventi.
We have intended to assess virological and clinical outcomes of DAAs treatment in HCV 
infected cirrhotics (both compensated and decompensated), in patients > 70 years and in 
cases of severe extrahepatic manifestations in a “real-life setting” with the aim to clarify:
1. virus kinetics of response and SVR rates
2. clinical outcomes in relation to virological response
3. long term benefits of treatment.
To do this, we have collected prospective data from a large cohort of patients treated with  
DAAs  in  the  Veneto  region.  This  was  made  possible  by  analysing  the  data  on  the 
NAVIGATORE web-platform coordinated by our Department (DMM).
The main end points of our analysis were:
1) Evaluation of virological outcomes and efficacy of DAA therapy:
- rates of viral eradication and virological response in the different subgroups of patients 
analysed  in  relation  to  stage,  HCV genotype  and  treatment  schedule  (SVR 12  = 
sustained virological response at week 12 after the end of treatment = EOT)
2) Evaluation of clinical outcomes including:
- changes in CHILD-PUGH and MELD scores,
-  variation  in  the  incidence  of  clinical  events  (hepatocellular  carcinoma,  portal  
hypertension, ascites, variceal bleeding, liver transplantation),
- safety and clinical outcome in patients with HCV and aged > 70 years,
-  assessment  of  clinical  outcomes  in  patients  with  extra-hepatic  HCV  related 
manifestations and disease (vasculitis, B-cell Lymphoma, cryoglobulinaemia).
Study design. The results  were obtained during an ongoing prospective observational 
study which includes all consecutive HCV patients treated since January 1 st 2015 with oral 
DAAs in  27 Clinical  Centers in  Veneto-Italy.  The study is  conducted according to  the 
ethical guidelines of the 1975 Declaration of Helsinki and obtained approval by the Ethics  
Committee. Individual  data are prospectively entered on the NAVIGATORE Platform at 
monthly intervals during antiviral therapy, 12 and 24 weeks after end of therapy and at 48 
week interval thereafter for a planned follow-up of 5 years. Data entry was monitored by  
several and standard quality control parameters, and by periodical audit meetings with the  
responsible clinicians. 
Patient selection. All consecutive HCV patients entered from January 1st 2015 to 24th May 
2017 in the NAVIGATORE data-base were evaluated. In the 3 months before initiation of  
antiviral  therapy all  patients underwent complete laboratory and clinical evaluation and 
abdomen ultrasound to  define  stage of  liver  disease and to  assess baseline  features 
guiding the treatment approach. If a suspected focal lesion was identified in the liver, the 
diagnostic work up was completed with another imaging technique, either computerized 
tomography (CT) scan or magnetic resonance imaging (MRI).
Antiviral  therapy  and  follow-up. All  patients  received  DAAs  treatment  according  to 
available  DAAs and  national  and  regional  guidelines,  that  were  defined and  updated 
periodically  and  implemented  in  specific  algorithms on  the  NAVIGATORE platform to  
optimise and to made homogeneous the regimens used by the participating Centers. . 
From  January  2015  to  the  end  of  February  2015  patients  were  treated  with  the 
combination of Sofosbuvir and Ribavirin, since the last week of February the treatment 
with  Sofosbuvir  plus  Simeprevir.  became  available  and  during  May  2015  the  other 
combinations of Sofosbuvir/Ledipasvir,  Sofosbuvir/Daclatasvir and then Ombitasvir plus 
Paritaprevir plus Ritonavir and Dasabuvir. were added to the Platform options. Patients  
were  treated  for  12  or  24  weeks,  with  or  without  addition  of  Ribavirin,  according  to 
guidelines and treater’s decision. The assigned schedule and any modifications during  
treatment were recorded on the NAVIGATORE Platform. Patients were seen (for visit and 
blood tests) monthly during therapy, and 12 and 24 weeks after termination of treatment  
and then at 6 months intervals.  During follow-up patients with F3 or cirrhosis at  entry  
continued to periodical (every 3 to 6 months) surveillance for HCC. 
Sustained Virological response (SVR) to therapy was defined as undetectable HCV-RNA 
by a quantitative real-time PCR with a limit of detection of 12 IU/ml. SVR was assessed at 
week 12 after EOT 
Statistical  analysis.  Results  are presented as median for  continuous variables and as 
frequency for categorical data. HCC characteristics were compared between patients with 
SVR  and  without  SVR  using  the  Student  t  test  or  the  Wilcoxon  rank-sum  test  for  
continuous variables. Categorical variables were compared using the Chi-squared test or  
the Fisher exact test if necessary. Baseline features associated with risk of complications  
and death were tested using univariate and multivariate Cox models. We estimated the 
incidence of HCC occurrence as cases per 100-patient-years with its  95% confidence 
limits, and described by the Kaplan-Meier method. The suspected influencing factors were 
tested by the Mantel test. We developed a proportional hazards multivariate Cox’s model,  
with the forward stepwise option, to select the most relevant factors for HCC development, 
and estimated their independent Hazard Ratios, with 95% confidence limits. A p value less 
than 0.05 was considered statistically significant.
RESULTS
At the time of this analysis, May 2017, 4764 HCV treated patients have been included.
- Demographic Data
Among the 4764 treated patients 62,4% are males and mean age is 58.18+/-10.8 years  
(range 21-90 years). The distribution of genotypes is as follows: 62,4% HCV-1 (41.3% 
HCV-1b, 19,2% HCV-1a), 13,3% HCV-2, 16,6% HCV-3, and 7.2% HCV-4.
62% had cirrhosis (87% CHILD A ,10% CHILD B and 4% CHILD C), and 25,7% had F3 
fibrosis at the time DAA were initiated.
Many patients (53%) had comorbidities with type 2 diabetes in  16,8%, cardiovascular 
disease  in  30%  obesity  in  8,2%  and  nephropathy  in  2,8%.  Extrahepatic  disease 
(lymphoma, vasculitis or cryoglobulinemic syndrome) was recorded in 3%.
Treated population 4764 pts %
Males/Females 2973/1791 patients 62,4 / 37,6
Mean Age +/- ds (years) 58,18+/-10,8 (range 21-90)
HCV-genotype 1a 19,2
1b 41,3
2 13,3
3 16,6
4 7,2
Stage of liver disease F3 (pre-cirrhosis) 25,7
F4 (cirrhosis) 62
Comorbidities extra-hepatic disease 3
type 2 diabetes 16,8
cardiovascolar disease 30
obesity 8,2%
nephropathy 2,8%
Table 3: Demographic Data
- Efficacy and Safety data in F3 and in Cirrhotic Patients
Patients  were  treated  according  to  the  implemented  algorythms  that  I  developed 
according to national  and regional  guidelines and were then monitored monthly during 
therapy and every 3 months thereafter.
At the time of this analysis patients had a mean follow-up of 398.8+115 days after the 
date  DAAs  were  initiated  and  SVR12  rates were  of  97.2% in  F3,  92.7% in  Child  A 
cirrhotics and 80% in Child B cirrhotics. Virus eradication with SVR12 was observed in  
94,8% with HCV-1a, in 98% with HCV-1b, in 95% with HCV-2, in 85,7% with HCV-3 and in 
95,4% with HCV-4. Premature therapy discontinuation occurred in 53 patients including:  
12 who died for hepatic causes, 11 who died for non-liver related causes, 4 patients who 
developed HCC and 21 patients who developed side-effects that were deemed severe 
and possibly or certainly drug-related by the treating physician. Mean follow-up after end  
of therapy was 338.2+768.6 days for patients who had reached EOT, and mean follow-up 
after SVR12 was 254.3+684.5 days for patients with SVR12 at the time of this analysis. 
Efficacy was excellent in most groups, not being significantly affected by comorbidities but 
it was reduced by around 10% in patients with Child B cirrhosis.
Tolerability and safety were excellent in patients with F3 and with Child A cirrhosis, while 
were  reduced  in  Child  B patients,  particularly  when  treated  with  Ribavirin  containing  
regimens (Table 4).
SAFETY
F3
F 4
Child A Child B
RBV yes RBV no RBV yes RBV no RBV yes RBV no
% Early 
Discontinuation
0 0,7 1,2 1,1 2,7 3,3
% Clinically
Significant
Side
Effects
3,6 0 3,9 1,8 7,6 0,9
% Ascites 0 0 1,3 1,8 10,9 4,9
Table 4: Safety of DAA according to stage liver disease and ribavirin (RBV) use.
Efficacy and Clinical Outcomes in Cirrhotic Patients
We have considered for these analysis 2946 cirrhotic patients.
Global SVR, according to genotype, was:
HCV-1a (524 patients): 94,8%
HCV-1b (1182 patients): 98%
HCV-2 (380 patients): 95%
HCV-3 (555 patients): 85,7%
HCV-4 (232 patients): 95,4%.
More detailed SVR rates, stratified by HCV genotypes and regimens, are presented in the  
following tables.
Drug regimens in HCV 1a Patient number SVR (%)
SOF/LDV 12 wks 21/524 100
SOF/LDV + rbv12 wks 101/524 97
SOF/LDV 24 wks 85/524 92,7
SOF/LDV + rbv 24 wks 97/524 98,3
3 D + rbv 12 wks 1/524 100 simple size bias
3 D + rbv 24 wks 110/524 100
3 D 24 wks 10/524 100 simple size bias
2 D+rbv 12/24 wks 1/11 /524 100 simple size bias
SOF/SMV +/- rbv 55/524 87
SOF/RBV 24 wks 10/524 33,3
SOF/DAC 12wks, 24 wks 1/3/524 100 simple size bias
SOF/DAC +rbv 24 wks 3/524 100 simple size bias
ELB/GRZ 10/524 ongoing
Table 5: % of SVR in genotype 1a patients according to regimens.
Drug regimens in HCV 1b Patient number SVR (%)
SOF/LDV 12 wks 51/1182 94,7
SOF/LDV + rbv12 wks 114/1182 95,2
SOF/LDV 24 wks 233/1182 97,6
SOF/LDV + rbv 24 wks 145/1182 98,1
3 D + rbv 12 wks 259/1182 98,6
3 D + rbv 24 wks 4/1182 66,7 simple size bias
3 D 24 wks 5/1182 100 simple size bias
3 D 12 wks 88/1182 91,2
2 D+rbv 12/24 wks 30/2/1182 100/50 simple sze bias
SOF/SMV +/- rbv 163/1182 92
SOF/RBV 24 wks 27/1182 39
SOF/DAC 12wks,  24  wks,  24 
wks+rbv
5/1182 100 simple size bias
ELB/GRZ 42/1182 ongoing
Table 6: % of SVR in genotype 1b patients according to regimens.
Drug regimens in HCV 2 Patient number SVR (%)
SOF/DAC 12 wks 80/380 93
SOF/RBV 12 wks 28/380 100
SOF/RBV 16- to 24 wks 55/380 94,9
SOF/RBV 24 wks 211/380 94,8
Table 7: % of SVR in genotype 2 patients according to regimens.
Drug regimens in HCV 3 Patient number SVR (%)
SOF/DAC24 wks 84/555 94,6
SOF/DAC + rbv 24 wks 329/555 94,2
SOF/DAC/RBV 12 wks 12/555 100 simple size bias
SOF/RBV 24 wks 89/555 64,2
SOF/LDV + rbv 24 wks 12/555 75 simple size bias
Table 8: % of SVR in genotype 3 patients according to regimens.
Drug regimens in HCV 4 Patient number SVR (%)
SOF/SIM +/- RBV 12wks 35/232 90,3
SOF/LED/RBV 12wks 100
SOF/LED 24wks 87,5
2D 12 wks 100
2D 24 wks 98,5
ELB/GRZ ongoing
Table 9: % of SVR in genotype 4 patients according to regimens.
- Outcomes in CHILD A and CHILD B cirrhosis
Child–Pugh and MELD scores are two scores with similar prognostic values, widely used 
for the assessment of prognosis in liver cirrhosis. Child–Pugh score was firstly proposed 
by Child and Turcotte and include: ascites, hepatic encephalopathy, total  bilirubin, INR 
and albumin. Child–Pugh score is mainly used to assess the severity of liver dysfunction 
in  clinical  work.  Model  for  end-stage  liver  disease  (MELD)  score  incorporate  only  3 
objective variables, including total bilirubin, creatinine, and INR. Currently, it is used to 
rank the priority of liver transplantation candidates. These scores are used to predict the 
clinical  outcomes in  cirrhotic  patients.  In  our  analysis,  we have  defined  patients  with 
compensated cirrhosis as “Child A” and those with decompensated cirrhosis as “Child B 
and C”.
In our population, the most part of patients are compensated (92,3% of cirrhosis are in  
Child A).
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The overall HCC incidence was of 1.64 x 100 patients/year (95% CI : 1.14-2.28). 
When patients were stratified according to the stage of liver disease at baseline, HCC 
incidence rates were:
0.23 x 100patients/year (95% CI 0,01-1,27) in F3, 
1.55 x 100patients/year (95% CI 1.18-2.01) in Child A cirrhosis and 
3,68 x 100 patients/year (95% CI : 1.92-6.41) in Child B cirrhosis. 
The  Kaplan  Meyer  curves  of  HCC occurrence  in  these  3  subgroups  of  patients  are 
described in Figure 3. There was a statistically significant difference in the probability of 
developing HCC between pre-cirrhotic F3 patients and cirrhotic patients (p = 0,0012) as  
well as between patient with compensated (C-P class A) and decompensated (C-P class 
B) cirrhosis (p = 0,013).
Figure 3: HCC occurrence in F3, Child A and Child B patients (Kaplan Meyer curves)
There were no statistically significant differences as to age, gender, HCV genotype, DAA 
schedule received.  However,  patients with  HCV-3 showed a trend towards higher  risk 
(HR: 1.69) compared to other genotypes. Among different baseline laboratory parameters 
analysed,  an  APRI value  above 2.5  was found associated  with  statistically  significant  
higher risk of developing HCC compared to a lower value (HR: 2.5 , 95% CI 1.21-5.14 p 
0.013). Other variables, such as liver stiffness measured by FIBROSCAN at baseline and 
prevalence  of  comorbidities  such  as  diabetes,  obesity  and/or  cardiovascular  disease, 
were not found to influenced the HCC risk.
When patients with and without SVR were compared, the risk of developing HCC was 
markedly  and  significantly  higher  in  the  latter  (incidence  in  NO-SVR:  8.73  x 
100patients/year, 95% CI: 5.47-13.26) compared to the former cases (incidence in SVR: 
1.30 x 100patients/year, 95% CI : 0.91-1.81 – HR 0.13 – 95% CI: 0.07-0.23 p= 0.001 ). By 
multivariate analysis, two baseline variables were statistically associated with HCC, i.e.  
an APRI score > 2.5 (HR 1.88, 95% CI: 1.03-3.42 p= 0.038) and Child B cirrhosis (HR 
2.11 with 95% CI:  1.00-4.46 p= 0.050).  The multivariate analysis after DAA treatment, 
confirms a risk for patients with an APRI score > 2.5 (HR 1.83, 95% CI: 0.89-3.75 p= 
0.099) and demonstrates the benefit of SVR (HR 0.20, 95% CI: 0.09-0.41 p= 0.001), as 
showed in the table 12.
BASELINE HR 95% CI p AFTER DAA TREATMENT HR 95% CI p
APRI score ≥ 2.5 1.88 1.03-3.42 0.038 APRI score ≥ 2.5 1.83 0.89-3.75 0.099
Child B 2.11 1.00-4.46 0.050 SVR-12 0.20 0.09-0.41 0.001
Table 12: Multivariate Cox’s regression (Forward stepwise selection)
Next table (table 13) described in detail  HCC incidence rates in our cirrhotic patients in  
relation to different variables.
Table 13: Risk of developing HCC in cirrhotic patients according to different variables.
The  52  patients  who  developed  HCC  during  the  observation  period  are  described 
individually in Table 14.
Patient
Age
(years)
Liver Disease
HCV
genotype
DAA 
treatment
SVR 12
wks from start DAA 
to diagnosis HCC
HCC 
Pattern
1 60 CHILD A 1a SOF/LDV no 4 3
2 51 CHILD B 3 SOF/DCV no 4 3
3 53 CHILD A 3 SOF + RBV no 6 3
4 66 CHILD A 2 SOF + RBV yes 10 1
5 57 CHILD A 3 SOF/DCV + RBV no 10 3
6 49 CHILD A 3 SOF + RBV no 10 1
7 54 CHILD A 1b SOF + RBV no 11 3
8 66 CHILD A 1b OBV/PTV/r/DSV + RBV yes 12 2
9 55 F3 4 SOF/LDV no 12 1
10 56 CHILD A 1a SOF/LDV + RBV yes 12 1
11 50 CHILD A 1a SOF/LDV no 12 2
12 61 CHILD A 1b OBV/PTV/r/DSV + RBV yes 13 2
13 44 CHILD A 1a SOF/Peg-IFN + RBV no 13 3
14 51 CHILD A 1b SOF/LDV + RBV yes 13 1
15 75 CHILD A 1b SOF/LDV + RBV no 14 3
16 79 CHILD A 2 SOF + RBV no 16 2
17 56 CHILD A 4 SOF/LDV + RBV yes 16 1
18 58 CHILD A 3 SOF + RBV no 18 3
19 65 CHILD A 1b OBV/PTV/r/DSV + RBV yes 21 1
20 67 CHILD B 1b SOF/LDV no 23 3
21 52 CHILD A 1b OBV/PTV/r/DSV + RBV no 23 1
22 75 CHILD A 1b SOF/LDV + RBV no 24 1
23 73 CHILD A 1b SOF/LDV yes 24 1
24 59 CHILD B 1b SOF + RBV no 24 1
25 51 CHILD A 1b SOF + RBV no 24 3
26 69 CHILD B 1b OBV/PTV/r/DSV + RBV yes 24 2
27 52 CHILD A 4 SOF/SMV + RBV no 25 1
28 50 CHILD A 1b SOF/SMV + RBV yes 25 3
29 56 CHILD A 3 SOF + RBV no 29 1
30 82 F3 2 SOF + RBV no 29 1
31 56 CHILD A 1b OBV/PTV/r/DSV + RBV yes 31 2
32 51 CHILD A 3 SOF/DCV + RBV yes 31 1
33 50 CHILD A 3 SOF + RBV no 32 1
34 59 CHILD A 1b OBV/PTV/r/DSV + RBV yes 36 3
35 75 CHILD A 1a SOF/LDV yes 37 1
36 51 CHILD A 3 SOF/DCV + RBV no 37 3
37 73 CHILD A 1b SOF/LDV yes 37 3
38 47 CHILD A 4 OBV/PTV/r/ + RBV yes 38 1
39 69 CHILD A 1b SOF/SMV + RBV yes 40 1
40 57 CHILD B 3 SOF/DCV + RBV yes 42 1
41 62 CHILD B 4 SOF + RBV yes 45 1
42 57 CHILD A 1b SOF/SMV + RBV yes 47 2
43 77 CHILD B 2 SOF + RBV yes 47 1
44 66 CHILD A 2 SOF + RBV yes 47 1
45 54 CHILD A 3 SOF/DCV + RBV no 49 2
46 53 CHILD A 3 SOF + RBV no 50 3
47 51 CHILD A 3 SOF/DCV + RBV yes 54 1
48 40 CHILD B 1b SOF/LDV + RBV yes 57 2
49 52 CHILD A 1b OBV/PTV/r/DSV + RBV yes 58 3
50 71 CHILD A 2 SOF + RBV yes 69 1
51 47 CHILD A 1a SOF/SMV + RBV no 71 1
52 66 CHILD A 3 SOF/DCV + RBV no 72 1
Table 14: desciption of 52 patients who developed HCC.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 and 5: different patterns of HCC in relation to time of they occurred (4) and in relation to virological  
outcomes (5).
Our prospective study, based on a large cohort of consecutive patients treated with DAAs, 
indicates that the risk of HCC during/after treatment with DAAs is comparable, or possibly 
lower, than that expected in the natural history of the disease, being strictly dependent on  
stage of liver disease. In patients with Child A cirrhosis,  our data base has recorded, 
during the first year after initiation of DAAs, an HCC rate of  1.55 x 100 patients/year with 
95% CI between 1.18 and 2.01, compared to an annual  incidence of 2.8% and 3.9% 
observed in 2 historical cohorts of untreated patients from the same geographic region. As 
regards patients with Child B cirrhosis treated with DAAs, the rate of HCC we observed 
was of 3.68 x 100 patients/year with 95% CI between 1.92 and 6.41, compared to an  
annual incidence of 5.7 % in an historical untreated cohort followed-up in our Institution 
between 2002 and 2014 (unpublished). A striking difference in our study was in the risk of 
HCC in relation to the response to antiviral therapy. Although HCC was observed in 26  
patients with SVR, the tumor incidence was significantly higher in patients without HCV 
eradication (figure 5). The incidence of HCC was not increased in our patients treated 
with  DAAs compared to  what  is  expected in  the  natural  course  in  HCV patients  with  
advanced liver disease, but the pattern of HCC was somehow unusual in a subgroup of 
patients who developed an aggressive type of tumor, that was multifocal or infiltrative at  
diagnosis. This pattern was observed in 16 patients, i.e. in <0.5% of the whole cohort of 
3682 patients, and prevailed in the early phase of observation, being diagnosed either  
during (7 cases) or immediately after (3 cases) antiviral therapy. 
- Clinical Outcomes in Extrahepatic Manifestations
Among  our  HCV  infected  patients,  we  have  recorded  287  patients  with  extrahepatic 
disease HCV-related. In particular, 76 patients with non-Hodgkin lymphoma (NHL-B), 106 
with clinically relevant vasculitis and 105 with cryoglobulinemia (mixed cryoglobulinemia 
syndrome with  cryocrit  value  higher  than  2%).  Mean  age  was 60,7+/-13,2  years  and 
genotype 1b was the most represented: 53% was genotype 1 (11% HCV-1a, 42% HCV-
1b) and 30% was genotype 2. Most of these patients had a mild form of liver disease and 
only 10% had a diagnosis of cirrhosis (F4), see table 15.
Cohort Extrahepatic Disease 287 (n. patients)
Non-Hodgkin lymphoma 76
Vasculitis 106
Cryoglobulinemia 105
Mean age (years) 60,7 +/- 13,2
Genotype 1a 11%
Genotype 1b 42%
Genotype 2 30%
Liver fibrosis stage F0 8.6%
F1 42,4
F2 30
F3 19
F4 10
Table 15: Features description in extrahepatic manifestations cohort
Among the 76 patients with NHL-B, we have recorded a complete remission in 28,6%, a  
partial  remission  in  44,1%,  unchanged  or  advanced  disease  in  10%  and  unknown 
outcome in 17,3%. 
Among  the  106  patients  with  significant  vasculitis,  we  have  recorded  a  complete 
remission in  17,4%, a partial  remission in  45,3%, unchanged or  advanced disease in 
5,8% and unknown outcome in 31,5%. 
Among the 105 patients with cryoglobulinemia, we have recorded a complete remission in 
49,5%, a partial remission in 25% and unknown outcome in 25,5%.
Non-Hodgkin lymphoma 76 patients complete remission 28,6%
partial remission 44,1%
unchanged or advanced 10%
unknown 17,3%
Vasculitis 106 patients complete remission 17,4%
partial remission 45,3%
unchanged or advanced 5,8%
unknown 31,5%
Cryoglobulinemia 105 patients complete remission 49,5%
partial remission 25%
unknow 25,5%
Table 16: Outcomes in patients with extrahepatic manifestations.
- Efficacy and Tolerability of DAA Treatment in the Elderly ( > 70 yrs)
Our data base has allowed us to analysed efficacy and safety in a subgroup of patients  
that has not been investigated in registration trials, i.e. an "elderly" subgroup aged > 70 
years.  1681 HCV patients aged > 70 years have been recorded on the NAVIGATORE 
platform and 942 of these have been treated with DAAs. Compared to younger patients  
recorded, these older 70 years had significantly higher prevalence of females (63% vs 
35%), naives (77% vs 65%), cirrhotics (49% vs 39%), previous HCC (3,8% vs 1,4%), 
HCV-1b (53% vs 34%) and HCV-2 (26% vs 7%), diabetes (12% vs 6%) and CVD (29% vs 
9%) and lower prevalence of HCV-1a (2% vs 22%) and HCV-3 (1% vs 19%).
Recorded patients <70 years >70 years
Patient number 6676 1681
% Females 35 63
% Naives 65 77
% Cirrhotics 39 49
% Previous HCC 1,4 3,8
% HCV-1a 22 2
% HCV-1b 34 53
% HCV-2 7 26
% HCV-3 19 1
% Diabetes/CVD 6/9 12/29
Table 17: Features of < 70 years people relation to > 70 years people in our population.
Patients were treated with approved DAAs according to guidelines and without significant  
differences in regimen choice with respect to patients < 70 years. Efficacy and safety were 
similar between patients < and > 70yrs without any statistically significant differences in 
SVR rates with different HCV genotypes. The elderly patients had more frequently an 
issue of  possible  drug-drug interactions  related to  the polytherapies they were on for 
several  comorbidities,  but  mortality  and  clinically  significant  adverse  events  were  not  
numerically different compared to younger patients.
HCV <70 years >70 years
1a 426/452 (94%) 11/13 (85%)
p = ns
1b 723/767 (94%) 287/279 (96%)
2 151/164 (92%) 147/158 (93%)
3 336/385 (87%) 6/8 (75%)
4 179/188 (95%) 3/3 (100/%)
Table 18: SVR rates according to age and genotype.
<70  years >70  years
Cases 3428 942
p = ns
Gastro-Intestinal bleeding0.5 % 0.1 %
Ascites 2.4 % 2.0 %
HCC 2.3 % 2.7 %
Liver related death 0.5 % 0.5 %
Other causes death 0.3 % 0.3 %
Table 19: Safety data according to age.
DISCUSSION
In this thesis we have assessed virological  and clinical  outcomes in a large cohort  of  
patients  with  hepatitis  C treated with  oral  DAAs combinations in  clinical  practise  with 
particular focus on 3 subgroups of patients: a) patients with advanced liver fibrosis or  
cirrhosis,  both compensated and decompensated, b)  patients with severe extrahepatic 
manifestations due to HCV, and c) patients with an age > 70 years. For this purpose I  
have  participated  since  the  very  beginning  to  the  design  and  development  of  the  
NAVIGATORE platform, a web-based platform that is monitoring patients with HCV as 
they are diagnosed, referred and treated with antiviral therapy in 27 Clinical Centers in  
our Region, in Veneto. The NAVIGATORE platform is used to monitor patients flows and 
treatment planning, while representing also a network that allows drugs use optimisation 
and  homogeneity  in  clinical  management.  It  permits  also  prospective  recording  of  
virological and clinical outcomes and of safety data. We considered a database records of  
4764 DAAs treated patients in Veneto Region from 1st January 2015 to 24th May 2017.
DAAs were safe and highly effective in eradicating HCV in all the different categories of  
HCV  infected  patients,  including  advanced  or  decompensated,  cirrhosis  as  well  as 
patients aged > 70 years Among the 4764 treated patients,  62% (2946 patients)  had 
cirrhosis  (87%  CHILD  A ,10%  CHILD  B  and  4%  CHILD  C)  and  many  patients  had 
comorbidities, but efficacy was excellent in most groups. As expected, SVR rates were 
somehow reduced in patients with Child B cirrhosis and with HCV-3 genotype. Tolerability 
and safety were also excellent in patients with F3 and with Child A cirrhosis, while were 
reduced in Child B patients, particularly when treated with Ribavirin containing regimens.
We  were  able  to  demonstrate  a  clear  reduction  in  the  incidence  of  major  clinical 
complications  in  DAA treated  patients,  compared  to  the  expected  rates  in  untreated 
patients. Among decompensated cirrhotic patients, many improved in Child-Pugh score 
during and after therapy, particularly when achieving SVR. Cirrhotic patients showed a  
reduced incidence of complications with DAA therapy, compared to what was expected 
according to the natural course of the disease.
Our analysis was particularly focused on the residual risk of developing HCC after HCV 
eradication by DAAs in patients with advanced fibrosis and cirrhosis.
In the past, evidence was obtained indicating that the risk of developing HCC in cirrhotic  
HCV patients was significant reduced, although not completely abolished, following HCV 
eradication  with  IFN-based  therapy.  It  was therefore  surprising  and at  the  same time 
alarming when Reig et al  reported “an unexpected high rate” of HCC recurrence early 
during or after DAAs in patients with a previous history of cured HCC and when Conti et 
al. seems to confirm that. These and some following reports (in most part retrospective 
and  often  including  small  series  of  patients  with  significant  heterogeneity  in  baseline  
features and available follow-up) described quite variable results, not allowing to draw 
any firm conclusion  on what  has become a  major  issue for  the  treatment  of  cirrhotic 
patients with DAAs,  i.e.  the residual  risk of  hepatocellular  carcinoma during and after  
treatment. We have analysed in details the incidence of HCC recurrence and that of “de 
novo” occurrence in patients with cirrhosis treated with DAAs in our database. The results 
of this analysis indicate that the risk of developing HCC during/after DAAs is not modified  
compared  to  what  is  expected  in  the  natural  course  of  the  disease,  being  largely  
dependent  on  stage of  liver  disease.  The  risk  of  developing  HCC was markedly  and 
significantly  higher  in  patients  with  more  advanced  liver  disease  and  without  SVR. 
Considering  that  most  of  our  patients  developed HCC early  in  the course of  antiviral  
therapy, a relation of cause and effect between HCC and virological failure rather than the  
opposite appears likely, and might reflect persistence in tumour cells of HCV virions less 
accessible/susceptible to antivirals, in line with other studies also. Although the incidence 
of  HCC  was  not  increased  in  our  patients  treated  with  DAAs  compared  to  what  is 
expected in the natural course in HCV patients with advanced liver disease, the pattern of  
HCC was somehow unusual in a subgroup of patients who developed an aggressive type 
of tumour, that was multi-focal or infiltrative at diagnosis. While 52% of them developed a  
single small HCC nodule and 17% developed 2-3 small HCC nodules, the remaining 31% 
were  diagnosed  with  larger  or  aggressive,  often  infiltrative,  tumours.  This  was  more 
frequent during rather  than after DAA treatment and in patients who did  not achieved  
SVR.
These tumours were most likely present already at baseline being still  microscopic or  
unrecognisable and it cannot be excluded that they might have been boosted in growth 
and spread by the profound immunological  and molecular  changes that are known to 
occur in the liver micro-environment following abrupt interruption of HCV replication by 
DAAs. Meanwhile our data, while clearly indicate that DAA treatment doesn’t increase 
HCC risk  in  cirrhotics,  reinforce  the  recommendation  that  cirrhotic  patients  should  be 
carefully  investigated at  baseline  to  exclude HCC and then continue to  be monitored 
during  and  after  therapy  independently  of  virological  outcome.  DAAs treatment  is  no 
pharmacological prevention of HCC even with successful antiviral therapy, and at least  
during the first 12 months after initiation of treatment, when microscopic and therefore  
initially invisible HCC foci might be present and emerge during or after antiviral therapy 
even  with  an  aggressive  pattern  of  growth  (27).  Further  data  and  analysis  on  the 
molecular, pathological and clinical characteristics of incident HCCs occurring during/after  
DAAs treatment are needed to better clarify these issues. This might be true both for “de 
novo” occurrence and for recurrence of HCC, this latter event being in our patients again 
not more frequent than expected in the natural history of the disease.
As other Authors have demonstrated, viral  eradication was not only associated with a 
reduction of liver-related consequences of  HCV infection, but  also with a reduction of 
relevant extrahepatic disease manifestations. SVR obtained with IFN-based therapy was 
associated with an improved overall survival and with an improved quality of life (28).
We  were  able  to  analyse  clinical  outcomes  in  287  patients  with  extrahepatic 
manifestations linked to HCV. In our preliminary analysis of disease outcomes, most of  
these patients showed a remission, partial  or  complete, of the extrahepatic syndrome,  
including  those  diagnosed  with  a  B  cell  lymphoma,  or  with  vasculitis.  Furthermore,  
patients  with  detectable  cryglobulins  at  baseline,  often  showed  disappearance  of 
circulating cryo during and after DAA therapy. These results need to be now consolidated 
and confirmed by longer  follow-up to  assess the precise role  and benefits of  antiviral  
therapy in these specific clinical settings.
Finally,  considering  that  in  our  Region,  as  in  most  parts  of  Italy,  the  HCV-infected 
population is ageing and the proportion of patients with advanced liver disease aged > 70 
years and presenting with several other comorbidities is particularly high, we decided to  
perform a sub-analysis  of  in  a  special  population.  Accordingly,  we have been able to 
describe efficacy, safety and clinical outcomes of DAA therapy in almost 1000 patients 
with HCV aged > 70 years. Our findings indicate excellent results of oral antiviral therapy  
in this clinical  settings, behaving in  a very similar way compared to younger patients,  
without any specific age related problematic issues. This was true also for patients > 70  
years with advanced liver disease, or cirrhosis. 
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